Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATX-295 in Advanced Solid Tumors
NCT06799065Phase 2Recruiting
- Sponsor
- Accent Therapeutics
- Start
- Mar 2025
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
A Phase 2 trial of ATX-295 in solid tumor, ovarian cancer, squamous cell carcinoma of the lung (SCCL), triple-negative breast cancer (TNBC), sponsored by Accent Therapeutics. Started Mar 2025; status: recruiting.
02
Drugs
ATX-295
03
Conditions
solid tumorovarian cancersquamous cell carcinoma of the lung (SCCL)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06799065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06799065.